预约演示

更新于：2026-06-28

Atezolizumab

阿替利珠单抗

更新于：2026-06-28

概要

基本信息

药物类型

单克隆抗体

别名

Anti-PDL-1-Genentech/Roche、Atezolizumab (Genetical Recombination)、Atezolizumab (genetical recombination) (JAN)

+ [11]

靶点

PDL1

作用方式

抑制剂

作用机制

PDL1抑制剂(程序性死亡配体1抑制剂)

治疗领域

肿瘤免疫系统疾病消化系统疾病+ [10]

在研适应症

结外NK-T细胞淋巴瘤晚期非小细胞肺癌乳腺癌+ [151]

非在研适应症

大肠腺癌晚期胆管癌晚期胆道癌+ [102]

原研机构

Genentech, Inc.

Universitair Medisch Centrum Groningen

在研机构

Genentech, Inc.Hoffmann-La Roche, Inc.

F. Hoffmann-La Roche Ltd.

+ [21]

非在研机构

SanofiRain Oncology, Inc.

Kymab Ltd.

+ [12]

权益机构

NeoImmuneTech, Inc.

Harpoon Therapeutics, Inc.Novocure, Inc.

+ [26]

最高研发阶段批准上市

首次获批日期

美国 (2016-05-18),

尿路上皮癌

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、附条件批准 (中国)、孤儿药 (日本)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)、优先审评 (中国)

登录后查看时间轴

结构/序列

Sequence Code 122091L

来源: *****

Sequence Code 4720027H

来源: *****

关联

919

项与阿替利珠单抗相关的临床试验

NCT07388524

/ Recruiting临床3期IIT

Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.

开始日期2027-03-02

申办/合作机构

National Cancer Institute

NCT07170592

/ Not yet recruiting临床1期

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Combination With Hydroxyurea or Hydroxyurea/Atezolizumab in Treatment-refractory Solid Tumor Patients

This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of cancer.

开始日期2027-01-01

申办/合作机构

Bionoxx, Inc.

NCT07322341

/ Not yet recruiting临床2期IIT

A Phase 2 Trial of SX-682 and Atezolizumab in Patients With Advanced NSCLC Who Progressed on Prior Chemotherapy and Immune Checkpoint Inhibitor (ICI) Therapy

This phase II trial tests how well SX-682 and atezolizumab works for the treatment of non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic), and has come back after a period of improvement (recurrent). SX-682 blocks proteins that may be able to stimulate the immune system to kill and eliminate tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SX-682 and atezolizumab may be effective for the treatment of advanced or metastatic, recurrent NSCLC.

开始日期2026-09-01

申办/合作机构

University of Washington

[+3]

100 项与阿替利珠单抗相关的临床结果

登录后查看更多信息

100 项与阿替利珠单抗相关的转化医学

登录后查看更多信息

100 项与阿替利珠单抗相关的专利（医药）

登录后查看更多信息

4,485

项与阿替利珠单抗相关的文献（医药）

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia

Article

作者: Chaiyakunapruk, Nathorn ; Patikorn, Chanthawat ; Sulaiman Shah, Audi Adawiah ; Wong, Yoke Fui ; Mohamed, Rosmawati

AIM:

This study aims to evaluate the cost-effectiveness of atezolizumab plus bevacizumab as first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC) in Malaysia, compared with the current standard treatments in the Malaysian Ministry of Health (MOH) to inform public healthcare decision‑making.

MATERIALS AND METHODS:

A cost-effectiveness analysis was conducted from the MOH perspective, following the national pharmacoeconomic guidelines (2019). The study compared atezolizumab plus bevacizumab with sorafenib and lenvatinib, respectively, using a partitioned survival model to project health outcomes and costs over a lifetime horizon. Clinical efficacy data were sourced from published trials and network meta-analyses. Cost inputs reflected local healthcare resource use and prices, using 2024 Malaysian Ringgit values inflated via the Consumer Price Index for Health. Costs and outcomes were discounted at 3% annually. Deterministic and probabilistic sensitivity analyses were performed to assess the impact of key parameter uncertainties on the results.

RESULTS:

Atezolizumab plus bevacizumab provided the highest quality-adjusted life years (QALYs) and life years compared to sorafenib and lenvatinib. Sorafenib was dominated by lenvatinib due to lower QALYs and higher costs and excluded from further analysis. Compared to lenvatinib, atezolizumab plus bevacizumab yielded 0.873 additional QALYs and RM 44,863 additional cost, resulting in an incremental cost-effectiveness ratio (ICER) of RM 51,399 per QALY gained (∼0.906 GDP/capita at Malaysia's 2024 GDP/capita RM 56,734).

CONCLUSIONS:

Atezolizumab plus bevacizumab is cost-effective compared to lenvatinib and sorafenib across willingness-to-pay (WTP) values of one to three times Malaysia's GDP per capita. These findings provide evidence to inform public health policy that expanding funding and adoption of atezolizumab plus bevacizumab is likely to improve health outcomes cost-effectively.

2026-09-01·COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY

Toxic effects of acute atrazine exposure on the physiological functions and transcriptional levels in non-targeted marine invertebrates (Chlamys nobilis)

Article

作者: Sun, Jing ; Zheng, Huaiping ; Liu, Yaoting ; Yan, Beiyu ; Lin, Qing ; Wang, Weili ; Zhang, Hongkuan

Atrazine (ATZ), the second most widely used pesticide globally, poses potential risks to non-target aquatic organisms. However, its toxicological impacts on the economically valuable Chlamys nobilis remain unknown. This study investigates the toxicological effects of ATZ on the economically important C. nobilis. We assessed tissue integrity, physiological functions, and transcriptional profiles following ATZ exposure. Mortality in C. nobilis was observed to be time- and dose-dependent. Gill tissue damage was first noted at 5 μg/L ATZ, with severity increasing at higher concentrations. Superoxide dismutase (SOD) and catalase (CAT) activities were significantly elevated at 5 μg/L and 50 μg/L compared to controls but declined at 500 μg/L (P < 0.05). Glutathione S-transferase (GST) activity increased in all exposed groups except at 500 μg/L, peaking at 5 μg/L (P < 0.05). Malondialdehyde (MDA) levels rose significantly at 0.5 μg/L and further increased with higher ATZ concentrations (P < 0.05). RNA-seq analysis revealed 167 and 282 differentially expressed genes (DEGs) at 0.5 μg/L and 50 μg/L, respectively, enriched in pathways related to the endocrine, sensory, and digestive systems. Our findings highlight the toxic effects of ATZ on C. nobilis and contribute to the environmental risk assessment of this pesticide.

2026-09-01·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synthesis and preclinical evaluation of 89Zr-DFO-atezolizumab for immuno-PET imaging in colorectal cancer

Article

作者: Hao, Siqi ; Rojsitthisak, Pornchai ; Vajragupta, Opa ; Chen, Qian ; Zhu, Hua ; Zhang, Qian ; Sriwongta, Soontaree ; Jiang, Yang ; Zhang, Yan ; Yang, Zhi

The immune checkpoint programmed ligand 1 (PD-L1) is expressed in various solid tumors and is associated with immunotherapy prognosis. Dynamic assessment of PDL1 expression levels helps identify patients who may benefit from immunotherapy. Atezolizumab is a monoclonal antibody that targets PD-L1 and is used in the treatment of various hematologic malignancies and solid tumors. However, research on colon cancer is lacking. Approximately 85% of colorectal cancer (CRC) patients have the MSS/pMMR (Microsatellite Stable/proficient Mismatch Repair) subtype, which lacks ideal biomarkers for precise and dynamic screening of potential immune-responsive subpopulations and for predicting combination therapy strategies. Currently, the assessment of PD-L1 is limited to biopsy samples. Molecular immuno-PET imaging can provide an effective solution for guiding clinical immunotherapy selection. This study describes the development of ⁸⁹Zr-DFO-atezolizumab, a PD-L1-targeted immuno-imaging agent, and its evaluation in terms of in vitro and in vivo specificity as well as pharmacokinetics. Tumor uptake and heterogeneity were quantified in mouse models via immuno-PET imaging. PET/CT scans using ⁸⁹Zr-DFO-atezolizumab revealed a significant difference in tumor uptake between the MC38^hPD-L1 model and the MC38 model, and cold anti-atezolizumab effectively blocked this uptake. The preliminary dosimetry study indicated that the organs receiving higher doses are the spleen and the liver. Preclinical PET/CT imaging with ⁸⁹Zr-DFO-atezolizumab reveals its potential for the non-invasive detection of PD-L1-positive CRC tumors, which holds potential significance for understanding tumor heterogeneity and monitoring early PD-L1 expression changes induced by therapy.

3,589

项与阿替利珠单抗相关的新闻（医药）

20 小时之前

·wukong的小筑

肿瘤临床与会议数据追踪 2026年06月27日

ESMO GI 倒计时 4 天 · ASCO Breakthrough 会议进行中速览T0Revolution Medicines RAS 管线 ESMO GI 数据全面曝光——Zoldonrasib 双药策略在胰腺癌创造历史性疗效，RASolute 305/309 III 期先后启动。T0斯鲁利单抗 EU 新增 sqNSCLC 适应症——第 4 个欧盟适应症、50 国获批、16 个欧洲国家上市销售。获批中国新药周：CT041 定价 99 万、BL-B01D1 获批（全球首个双抗 ADC）、LM-302 NDA 受理——实体瘤 CAR-T、双抗 ADC、CLDN18.2 ADC 同周亮相。ESMO GI 2026 口头摘要全量发布：3 项 LBA + 7/2-7/4 优选 / 快速口头报告日程梳理。🔥 T0 进展1. Revolution Medicines RAS 管线 ESMO GI 数据全面曝光 Revolution Medicines 于 6/24 发布 ESMO GI 4 项数据预告后，6/26 学术经纬等媒体获取摘要全文数据，Zoldonrasib（RMC-9805，RAS G12D 选择性抑制剂）与 Daraxonrasib（RMC-6236，泛 RAS 抑制剂）双药策略在胰腺癌（mPDAC）疗效数据全面揭晓，被视为"癌王"治疗的历史性突破。RAS G12D 突变约见于 40% 的胰腺导管腺癌患者。340O：Zoldonrasib + 化疗，一线 RAS G12D mPDAC（Wolpin, Boston）队列nORRDCRVAF 下降≥50%VAF 完全清除Zoldonrasib + mFFX2882%96%100%47%Zoldonrasib + GnP1861%90%100%71% mFFX = 改良 FOLFIRINOX；GnP = 吉西他滨 + 白蛋白结合型紫杉醇。两组均实现 100% 患者 RAS G12D VAF 下降 ≥50%，提示药物在分子层面深度清除 RAS 突变克隆。RASolute 305 III 期已于 2026-06-25 启动，评估 Zoldonrasib + 化疗 vs 安慰剂 + 化疗一线 RAS G12D mPDAC。341O：Zoldonrasib + Daraxonrasib，二线及以上 KRAS G12D mPDAC（Azad, Baltimore）治疗线nORRDCR6m-PFS6m-OS二线（2L）3050%97%71%89%三线及以上（3L+）1547%90%59%82% 对比历史数据：后线 PDAC 化疗 ORR 通常仅 3-8%，mPFS 2-4 个月，mOS 5-7 个月。RASolute 309 III 期计划 2026H2 启动，评估 Zoldonrasib + Daraxonrasib vs GnP 一线 RAS G12D mPDAC。评述：RAS(ON) 双药策略（G12D 选择性 + 泛 RAS）在胰腺癌展现前所未有的协同活性——二线 ORR 50% 远超单药或历史化疗水平。若 III 期验证，RAS G12D mPDAC 治疗格局将被彻底改写。来源：学术经纬 (6/26) | Revolution Medicines IR (6/24, 6/25)2. ASTRUM-006：斯鲁利单抗 EU 版图再扩容获批复宏汉霖 PD-1 单抗斯鲁利单抗（Serplulimab，汉斯状®）于 6/25 获欧盟批准鳞状非小细胞肺癌（sqNSCLC）适应症，为其在欧盟的第 4 个适应症，实现肺癌核心亚型全覆盖。斯鲁利单抗已在 50 个国家获批、16 个欧洲国家上市销售，是全球首个且唯一获批胃癌围术期适应症的 PD-1 单抗（NMPA 2026-06-09 批准，pCR 21.6%，HR 0.67/0.63），累计研发投入约 37.30 亿元。ESMO GI 预期更新长期 EFS/OS 数据。来源：复宏汉霖公告 (6/26)3. HERIZON-GEA-01 / MATTERHORN / QLS31905 摘要预览 HERIZON-GEA-01（Zanidatamab + 替雷利珠单抗 ± 化疗，HER2+ mGEA）：百济神州 HER2 双抗。已知数据 mPFS 12.4 月（HR 0.63），mOS 26.4 月（HR 0.72），已发表于 NEJM，FDA PDUFA 2026-08-25。ESMO GI 两项摘要：494O（7/3 Oral，Shitara，HRQoL 分析）+ 495RO（7/4 Rapid Oral，Pietrantonio，疗效特征与 PFS2 探索性分析）。 MATTERHORN（Durvalumab + FLOT，围手术期 GEA）：阿斯利康 PD-L1 单抗，EFS 阳性——首个阳性围手术期免疫 III 期 GEA 研究。ESMO GI 预期更新 EFS/OS/安全性详细数据。 QLS31905（CLDN18.2/CD3 双特异性 TCE + 化疗，一线胃癌）：齐鲁制药 CLDN18.2/CD3 T 细胞衔接器，Ib/II 期胃癌 ORR 80%，mPFS 10.09 月。ESMO GI 预期更新详细数据，CLDN18.2 赛道持续升温。4. RASolute 302：Daraxonrasib 单药后线 mPDAC Revolution Medicines 泛 RAS 抑制剂 Daraxonrasib（RMC-6236）单药治疗经治 mPDAC：mOS 13.2 vs 6.7 月（HR 0.40），已发表于 NEJM；FDA 扩展用药项目（EAP）2026-05 开放。Daraxonrasib 与 Zoldonrasib 的联用数据已在 341O 展现协同潜力，构成 Revolution Medicines RAS 管线的"三驾马车"——单药（Daraxonrasib）、G12D 选择性（Zoldonrasib）、双药联合，对应 III 期 RASolute 302/305/309 布局。🎯 ESMO GI 2026 口头摘要预览 ESMO GI 2026 将于 7 月 1-4 日在德国慕尼黑召开。距开幕 4 天，摘要已全量释放，KOL/媒体解读持续上线。重磅 LBA（Late-Breaking Abstracts）LBA研究方案瘤种讲者LBA1KRYSTAL-10Adagrasib + Cetuximab vs 化疗KRAS G12C mCRC 二线TaberneroLBA2EMERALD-3Tremelimumab + Durvalumab ± Lenvatinib + TACEeeHCC（早期/中期 HCC）ErinjeriLBA4TRIPP-FFXP-32 微粒 + FOLFIRINOXuLAPC（不可切除局部晚期胰腺癌）Milella7 月 2 日优选口头报告（14:00-15:30 | 14 会议室）摘要号研究/药物瘤种LBA2EMERALD-3：Tremelimumab + Durvalumab ± Lenvatinib + TACEeeHCC183OEMERALD-1 OS：Durvalumab + Bev + TACEeeHCC340OZoldonrasib + 化疗 1LRAS G12D mPDAC341OZoldonrasib + Daraxonrasib 2L+KRAS G12D mPDAC342OGLEAM：Zolbetuximab + GNCLDN18.2+ mPAC（胰腺癌）7 月 3 日优选口头报告（16:30-18:00 | 14 会议室）摘要号研究/药物瘤种8OGALAXY OS：ctDNA 指导CRLM 术后LBA1KRYSTAL-10：Adagrasib + CetuximabKRAS G12C mCRC 二线1OATOMIC：Atezolizumab 辅助dMMR 结肠癌493OSTAR-221：Domvanalimab + Zimberelimab + 化疗HER2- GEA 一线494OHERIZON-GEA-01 HRQoL：Zanidatamab + 化疗 ± TISHER2+ mGEA7 月 4 日创新快速口头报告（08:30-10:00 | 13a）摘要号研究/药物瘤种LBA4TRIPP-FFX：P-32 微粒 + FOLFIRINOXuLAPC6ROKANDLELIT-001：Calderasib（MK-1084）KRAS G12C mCRC495ROHERIZON-GEA-01 探索性分析：ZanidatamabHER2+ mGEA343ROFanregratinib 关键 II 期（徐建明，北京）🇨🇳FGFR2+ ICC344ROFutibatinib + Zimberelimab + 化疗1L BTC345ROPROCEADE PDAC：Precemtabart TocentecanmPDAC7ROBREAKWATER 分子分析：Encorafenib + CetuximabBRAF V600E mCRC496ROEORTC ASPIRE：PD-L1 检测互通性GEA295ROTORCH-iTNT 更新（张臻，上海）🇨🇳LARCT2 值得关注（精选）343RO（7/4）：凡瑞格拉替尼（Fanregratinib/HMPL-453） FGFR2 抑制剂关键 II 期 FGFR2+ ICC 数据，讲者徐建明（北京），和黄医药，NDA 已纳入优先审评。183O（7/2）：EMERALD-1 OS 更新，Durvalumab + Bev + TACE eeHCC（Sangro, Pamplona）。345RO（7/4）：PROCEADE PDAC，Precemtabart Tocentecan（靶向 Claudin18.2 的新型 ADC）治疗 mPDAC（Wainberg, LA）。295RO（7/4）：TORCH-iTNT 免疫 TNT ± SCRT LARC 更新（张臻，上海）。🇨🇳 中国药企动态1. 科济药业 CT041 定价 99 万元/人份——全球首款实体瘤 CAR-T 获批科济药业 CLDN18.2 CAR-T 舒瑞基奥仑赛（CT041）于 2026-06-22 获 NMPA 批准（全球首款实体瘤 CAR-T），用于后线 CLDN18.2 阳性胃癌/胃食管结合部腺癌。定价 99 万元/人份（挂网价），预计 2026 年 200 单，中国内地峰值销售约 20 亿元。关键临床数据：mITT PFS 3.25 vs 1.77 月（HR 0.37），OS 7.92 vs 5.49 月；ASCO 一线序贯方案中位 PFS 达 20.9 月，ORR 100%，40% 患者转化手术。已纳入 CSCO 2026 指南注释。通用型 CAR-T IND 已提交（BCMA / CD19-CD20），体内 CAR-T 处于临床前。6/26 澎湃新闻发布李宗海教授长篇专访。2. CLDN18.2 赛道最新格局（截至 6/27）药物类型状态企业定价Zolbetuximab单抗美/欧/日/中已上市安斯泰来—舒瑞基奥仑赛（CT041）CAR-T✅ 中国获批（6/22）科济药业99 万/人份IBI343ADCNDA 已递交信达 / 美德纳—LM-302（维特柯妥拜单抗）ADCNDA 受理（6/23）中国生物制药—BL-M05D1ADC临床中百利天恒—QLS31905CD3 TCEII/III期齐鲁制药—3. 中国药企 ESMO GI 2026 参与企业药物ESMO GI 摘要等级最新动态复宏汉霖斯鲁利单抗（ASTRUM-006）预期口头报告⭐⭐⭐EU sqNSCLC 获批（6/25）百济神州Zanidatamab（HERIZON-GEA-01）494O + 495RO⭐⭐⭐—齐鲁制药QLS31905 TCE预期更新⭐⭐⭐—和黄医药凡瑞格拉替尼（Fanregratinib）343RO（徐建明）⭐⭐⭐NDA 优先审评康方生物Cadonilimab（COMPASSION-15）预期亚组更新⭐⭐—百利天恒BL-M05D1 CLDN18.2 ADC预期更新⭐⭐BL-B01D1 获批（6/22）科济药业CT041 CAR-T预期更新⭐⭐6/22 获批，99 万/针信达 / IncytePemigatinib（FIGHT-302）预期 PFS/OS 更新⭐⭐ORR 47%4. 其他中国药企重磅事件获批百利天恒 BL-B01D1（伦康依隆妥单抗）于 2026-06-22 获 NMPA 批准——全球首个双抗 ADC，EGFR×HER3 双靶点，适应症为鼻咽癌（NPC）。百利天恒因此重回千亿市值。中国生物制药 LM-302（维特柯妥拜单抗） CLDN18.2 ADC 于 2026-06-23 获 NMPA NDA 受理。和黄医药凡瑞格拉替尼（Fanregratinib/HMPL-453） FGFR2 融合 ICC 关键 II 期注册研究 7/4 ESMO GI 343RO 公布（讲者徐建明），NDA 已于 2025 年 12 月纳入优先审评。

2026-06-26

·丁香园肿瘤时间

局限期小细胞肺癌专家共识：从分期、治疗到并发症管理的八大核心问题解读

小细胞肺癌（SCLC）是一种恶性程度高、侵袭性强、预后差的恶性肿瘤，其中局限期小细胞肺癌（LS-SCLC）占 30% ~ 40%[1]。LS-SCLC 行根治性放化疗后仍面临较高的复发转移风险，患者的中位总生存期（OS）仅为 25 ~ 30 个月[1]。随着 ADRIATIC 研究发表，确立了度伐利尤单抗作为放化疗后免疫巩固治疗的标准模式，为接受铂类药物为基础的放化疗后未出现疾病进展的 LS-SCLC 患者的生存改善提供了新策略。然而，在 LS-SCLC 诊疗临床实践中，仍面临精准分期、放疗策略优化、免疫治疗介入时机等诸多问题亟需解决[1]。在此背景下，中国临床肿瘤学会（CSCO）小细胞肺癌专家委员会制定了《局限期小细胞肺癌临床诊疗中国专家共识》（以下简称「共识」），以期为临床医师提供权威、可行的指导建议，进一步提升诊疗规范化水平[1]。八大核心临床问题与共识推荐意见问题 1 在当前诊疗技术背景下，如何界定 LS-SCLC？推荐意见：建议将 TNM 分期 Ⅰ ~ Ⅲ 期（无论是否伴有同侧和／或对侧肺门、纵隔、锁骨上区淋巴结转移）且适合接受根治性放疗的 SCLC 归类为 LS-SCLC。推荐行 PET-CT 检查以提高分期准确性，必要时可联合超声支气管镜（EBUS）等有创手段进一步明确[1]。解读：精准分期是制定 LS-SCLC 治疗策略的前提。为克服传统 VALG 法分期在准确性和适用性上的局限，共识建议采用 VALG 分期与 TNM 分期系统相结合的综合分期标准。充分的影像学评估确实是实现 SCLC 精准分期的关键前提。研究数据显示，PET-CT 检查可使约 20% 常规影像学诊断为 LS-SCLC 的患者重新分期为广泛期小细胞肺癌（ES-SCLC），超过 10% 的 ES-SCLC 患者下调为 LS-SCLC，27% 的患者因 PET-CT 结果调整治疗策略[1-3]。共识鼓励条件允许时采用 PET-CT 检查进行分期，并酌情联合 EBUS 等有创检查，以最大程度提高分期准确性，为后续精准治疗决策提供依据。问题 2 哪些 LS-SCLC 患者可考虑进行手术治疗？推荐意见：建议确诊为 T1-2N0M0 的 LS-SCLC 患者考虑以手术为主的综合治疗模式。对于分期超过 T1-2N0M0 的患者，推荐以同步放化疗为主的治疗方案；新辅助免疫治疗联合化疗后再手术的模式目前尚处于探索阶段[1]。解读：一项基于美国国家癌症数据库的大型回顾性分析显示，对于分期为 T1-2N0M0 的 LS-SCLC 患者，手术联合辅助化疗组的 5 年 OS 率显著高于同步放化疗组（P ＜ 0.01）；但该分析可能存在患者选择偏倚等问题，其结果仍需前瞻性随机对照研究进一步验证[1,4]。基于现有证据，共识推荐对 LS-SCLC 患者实施分层治疗：T1-2N0M0 患者采用以手术为主的综合治疗，分期超过 T1-2N0M0 的患者接受同步放化疗为主的治疗方案。此外，新辅助免疫联合化疗能否成为 LS-SCLC 的常规治疗方案，尚待前瞻性随机对照研究验证。问题 3 LS-SCLC 术后患者如何制定治疗方案，是否可进行免疫治疗？推荐意见：对于 R0 切除术后患者，pN0 期推荐行辅助化疗，pN1期推荐行辅助化疗 ± 放疗，pN2 期及以上推荐行辅助放化疗。目前，对于完成标准辅助治疗后是否联合免疫治疗，尚缺乏临床证据，因此鼓励开展相关的临床研究[1]。解读：针对术后治疗，共识基于手术切除完整性及淋巴结病理分期（pN0、pN1 、pN2 及以上），推荐实施精细化分层管理。对于 R0 切除患者，pN0 期仅推荐行辅助化疗，pN1 期推荐辅助化疗基础上可酌情考虑辅助放疗，pN2 期及以上推荐辅助放化疗。关于术后免疫治疗，对于 R0 切除患者，目前尚缺乏高级别证据支持术后辅助免疫治疗，因此共识鼓励开展相关临床研究探索，并未予以常规推荐。问题 4 LS-SCLC 患者如何制定胸部放疗方案？推荐意见：对于不适合或拒绝手术治疗的 T1-2N0M0 患者，推荐体部立体定向放疗（SBRT）或常规分割放疗联合化疗。对于分期超过 T1-2N0M0 者，推荐同步或序贯放化疗。胸部放疗推荐采用 45 Gy/30 次、bid，或 60 ~ 70 Gy/30 ~ 35 次、qd 方案；在安全可行前提下，可考虑对 GTV 同步加量至 54 Gy/30 次、bid；60 Gy/40 次、bid 和 45 Gy/15 次、qd 可作为临床潜在可选方案。对于诱导化疗后放疗的患者，推荐基于化疗后病变范围勾画原发灶靶区，基于化疗前受累的淋巴结区或淋巴结勾画淋巴结靶区，并应尽量避免照射未受累的淋巴结或淋巴结区[1]。解读：对于 LS-SCLC 胸部放疗方案，在放射剂量与分割模式方面存在多种临床选择。除常规推荐方案（45 Gy/30 次、bid 或 60~70 Gy/30~35 次、qd）外，共识还纳入了同步加量方案（54 Gy/30 次、bid）以及潜在可选方案（60 Gy/40 次、bid 和 45 Gy/15 次、qd）。在放疗靶区勾画方面，为减少对危及器官的照射剂量，共识推荐针对原发灶勾画化疗后的残留肿瘤，而对淋巴结靶区建议勾画化疗前受累的淋巴结区，同时尽量避免对未受累淋巴结/淋巴结区的照射。此外，质子放疗、自适应性放疗等新型放疗技术可能成为 LS-SCLC 的潜在治疗选择。问题 5 LS-SCLC 患者经放化疗后免疫巩固治疗的介入时机？推荐意见：对于放化疗后未出现疾病进展的 LS-SCLC 患者，推荐采用度伐利尤单抗进行 2 年巩固治疗。同时，推荐在完成放化疗后 42ｄ内启动免疫治疗。若未能于此时间内开始，建议在条件允许后尽早启用[1]。解读： ADRIATIC 研究显示，在完成同步放化疗后未出现疾病进展的 LS-SCLC 患者中，度伐利尤单抗作为巩固治疗相较安慰剂可显著改善中位 OS（55.9 个月 vs 33.4 个月；HR = 0.73；P = 0.01）和中位无进展生存期（PFS，16.6 个月 vs 9.2 个月；HR = 0.76；P = 0.02）[1,5]。基于该高级别循证证据，共识推荐采用度伐利尤单抗进行 2 年巩固治疗；同时，参考 ADRIATIC研究设计，共识推荐完成放化疗后 42ｄ内启动免疫巩固治疗；若未能在此时间窗内启动，应在条件允许后尽早启用。值得一提的是，特瑞普利单抗[6]、斯鲁利单抗[7]及贝莫苏拜单抗[8]等免疫检查点抑制剂作为同步放化疗后巩固治疗，在小样本探索性研究中也显示出初步积极结果，但尚需大样本、多中心 Ⅲ 期研究进一步验证。另外，ACHILES（阿替利珠单抗）[9]等研究结果为阴性，提示并非所有免疫巩固治疗方案均能获益。问题 6 LS-SCLC 是否可以考虑应用免疫联合放化疗模式？推荐意见：放化疗后行度伐利尤单抗巩固治疗为当前 LS-SCLC 的标准治疗模式。基于现有临床数据，目前不推荐将免疫诱导或同步联合放化疗模式作为常规治疗方案[1]。解读：将免疫治疗前移至与放化疗同步应用的模式，目前尚缺乏充分的证据支持；如 NRG LU005 Ⅲ 期研究显示，在同步放化疗基础上联合阿替利珠单抗未改善 LS-SCLC 患者生存[1,10]。因此，共识明确目前不推荐免疫诱导或同步联合放化疗作为常规方案。问题 7 对于拟行免疫巩固治疗的 LS-SCLC 患者，是否推荐行脑预防照射（PCI）？其与免疫巩固治疗的时序应如何安排？推荐意见：对于放化疗后达到完全缓解或部分缓解并计划行度伐利尤单抗巩固治疗的患者，推荐行 PCI 或考虑颅脑 MR 密切随访。高龄、早期（如 Ⅰ 期）、PS 3 ~ 4 分或神经认知功能受损的患者不推荐 PCI。未行 PCI 者推荐采用颅脑增强 MR（若有禁忌则采用增强 CT）进行密切随访。对于计划行 PCI 与度伐利尤单抗巩固治疗的患者，目前无明确时序证据。建议在完成放化疗后尽早启动治疗，具体顺序可根据临床情况决定[1]。解读：对于脑预防照射，共识提出个体化选择策略：对放化疗后达到完全缓解或部分缓解并计划行度伐利尤单抗巩固治疗的患者推荐行 PCI，而其中高龄、分期较早、体力状况评分较差或已存在神经认知功能受损的患者不推荐常规行 PCI。关于 PCI 与免疫巩固治疗的时序，目前尚无统一标准，可视具体临床情况而定。问题 8 LS-SCLC 患者在放化疗后免疫治疗期间出现肺炎如何处理？推荐意见：需鉴别感染性肺炎和非感染性肺炎。若为感染性肺炎，尽早行抗感染治疗。若为非感染性肺炎（放射性肺炎和／或免疫相关性肺炎），推荐根据严重程度分级处理：≥ 2 级患者应暂停免疫治疗，并给予糖皮质激素治疗；可考虑联用抗纤维化药物（如吡非尼酮或尼达尼布）。≥ 3 级患者需住院治疗，并停用免疫治疗，首选静脉给予糖皮质激素。若糖皮质激素疗效不佳，可考虑使用吗替麦考酚酯或托珠单抗等药物治疗[1]。解读：对于放化疗后免疫治疗期间出现的肺炎，管理核心是先鉴别感染性与非感染性肺炎，再制定相应处理策略。针对感染性肺炎，应尽早抗感染治疗；针对非感染性肺炎（如放射性肺炎、免疫相关性肺炎），则按严重程度分级处理。结语针对 LS-SCLC 诊疗，共识围绕与精准分期、手术与放疗策略、免疫巩固治疗介入时机等相关的八大核心临床问题，形成了基于当前循证证据的推荐意见，构建了从分期、治疗到并发症管理的全流程决策路径。展望未来，随着新型药物研发、精准放疗技术革新以及生物标志物研究的深入，LS-SCLC 的精准诊疗水平有望进一步提升，为患者带来更大的生存获益与更好的生活质量。 ✩ 本文仅供医疗卫生等专业人士参考审批编号：CN-185127 过期日期：2026-09-02 本材料由阿斯利康提供，仅供医疗卫生专业人士进行医学科学交流，不用于推广目的。内容策划：nyh 项目审核：杨静参考文献： [1] 中国临床肿瘤学会小细胞肺癌专家委员会. 局限期小细胞肺癌临床诊疗中国专家共识[J]. 中华肿瘤防治杂志,2026,33(02):69-77. [2] Kalemkerian GP, Gadgeel SM. Modern staging of small cell lung cancer[J]. J Natl Compr Canc Netw. 2013 Jan 1;11(1):99-104. [3] Kalemkerian GP. Staging and imaging of small cell lung cancer[J]. Cancer Imaging. 2012 Jan 12;11(1):253-8. [4] Yang CJ, Chan DY, Shah SA, et a. Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer[J]. Ann Surg. 2018 Dec;268(6):1105-1112. [5] Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer[J]. N Engl J Med. 2024 Oct 10;391(14):1313-1327. [6] Zhang P, Liu F, Wang D, et al. A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer[J]. J Clin Oncol. 2024;42(16_suppl):8098. [7] Wu Y, Deng L, Wang J, et al. 1795P Consolidation serplulimab following concurrent hypofractionated chemoradiotherapy for limited-stage SCLC: Preliminary analysis of phase II ASTRUM-LC01 study[J]. Ann Oncol. 2024;35:S1067. [8] Liu X, Yin X, Zhuang L, et al. Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study[J]. BMC Cancer. 2025 Mar 20;25(1):509. [9] Gronberg BH, Aanerud M, Dumoulin DW, et al. Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC)[J]. J Clin Oncol. 2025;43(17_suppl):LBA8005. [10] Higgins K, Hu C, Ross HJ, et al. Concurrent Chemoradiation ± Atezolizumab (atezo) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005[J]. Int J Radiat Oncol Biol Phys. 2024;120( 2_Suppl):S2.

2026-06-25

·allsci.com

Merck’s Keytruda-Padcev combo becomes first PD-1/ADC regimen for cisplatin-ineligible bladder cancer

The European Commission has approved Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin) as perioperative treatment for adults with resectable muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy — marking the first PD-1 inhibitor plus antibody-drug conjugate regimen authorized in this setting across all 27 EU member states. The decision, which follows a positive CHMP recommendation in May 2026, extends a November 2025 US FDA approval to the European market and positions Merck (NYSE: MRK) alongside co-developers Pfizer and Astellas in a disease area where surgery alone has been the longstanding standard of care for cisplatin-ineligible patients. Clinical evidence The approval rests on data from KEYNOTE-905/EV-303 (NCT03924895), an open-label, randomized Phase III trial enrolling 595 patients with cisplatin-ineligible resectable MIBC. Patients in the combination arm received three neoadjuvant cycles of pembrolizumab plus enfortumab vedotin before radical cystectomy, followed by six adjuvant cycles of the combination and then eight cycles of pembrolizumab alone. The primary endpoint was event-free survival (EFS) versus surgery alone. The combination reduced the risk of EFS events by 60% (HR=0.40; 95% CI, 0.28–0.57; p<0.0001), with median EFS not reached versus 15.7 months for surgery alone. Overall survival data were similarly statistically significant, with a 50% reduction in the risk of death (HR=0.50; 95% CI, 0.33–0.74; p=0.0002). Pathologic complete response rate reached 57.1% in the combination arm versus 8.6% with surgery alone — a difference that carries practical relevance given the established association between pCR and long-term outcomes in MIBC. Mechanism and combination rationale Pembrolizumab blocks the PD-1 receptor, restoring T-cell-mediated antitumor immunity, while enfortumab vedotin delivers a cytotoxic payload — monomethyl auristatin E — directly to tumor cells via a Nectin-4-targeting antibody. Nectin-4 is broadly expressed in urothelial carcinoma, and the two mechanisms are considered complementary: ADC-mediated tumor cell death may enhance antigen release and immune priming, potentially amplifying checkpoint inhibitor activity. Competitive context The approval arrives in a bladder cancer landscape that is becoming increasingly competitive across disease stages. Bristol Myers Squibb’s nivolumab (Opdivo) holds FDA approval for adjuvant treatment of high-risk urothelial carcinoma following radical resection, including in cisplatin-ineligible patients, but covers only the post-surgical phase without a neoadjuvant component. The perioperative arc of the pembrolizumab plus enfortumab vedotin regimen — spanning both pre- and post-surgical treatment — has no direct approved equivalent in this cisplatin-ineligible population. AstraZeneca’s durvalumab (Imfinzi) in combination with enfortumab vedotin is being evaluated in the same cisplatin-ineligible MIBC setting in the VOLGA trial, as previously reported, representing the closest active clinical comparator to KEYNOTE-905. Meanwhile, Genentech’s atezolizumab (Tecentriq) recently received FDA approval as adjuvant therapy for MIBC, adding further regulatory momentum to the checkpoint inhibitor field in this disease. Enfortumab vedotin’s role is also expanding: Astellas has indicated that Padcev is central to its post-Xtandi growth strategy, with an FDA priority review underway for the cisplatin-eligible MIBC setting based on the EV-304 trial (PDUFA August 17, 2026). For Merck, the EU authorization consolidates pembrolizumab’s position across the MIBC continuum and adds a major market to an indication where the clinical differentiation from surgery alone is among the most pronounced reported in perioperative bladder cancer trials to date. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

100 项与阿替利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10773	阿替利珠单抗	L01XC32	DB11595

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
结外NK-T细胞淋巴瘤	日本	Chugai Pharmaceutical Co., Ltd.	2025-09-19
晚期非小细胞肺癌	欧盟	Roche Registration GmbH	2024-07-25
晚期非小细胞肺癌	冰岛	Roche Registration GmbH	2024-07-25
晚期非小细胞肺癌	列支敦士登	Roche Registration GmbH	2024-07-25
晚期非小细胞肺癌	挪威	Roche Registration GmbH	2024-07-25
乳腺癌	加拿大	F. Hoffmann-La Roche Ltd.	2024-03-13
肺泡软组织肉瘤	美国	Genentech, Inc.	2022-12-09
PD-L1阳性非小细胞肺癌	日本	Chugai Pharmaceutical Co., Ltd.	2022-05-26
BRAF V600 突变阳性黑色素瘤	美国	Genentech, Inc.	2020-07-30
PD-L1阳性三阴性乳腺癌	日本	Chugai Pharmaceutical Co., Ltd.	2018-01-19
晚期肝细胞癌	欧盟	Roche Registration GmbH	2017-09-20
晚期肝细胞癌	冰岛	Roche Registration GmbH	2017-09-20
晚期肝细胞癌	列支敦士登	Roche Registration GmbH	2017-09-20
晚期肝细胞癌	挪威	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	欧盟	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	冰岛	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	列支敦士登	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	挪威	Roche Registration GmbH	2017-09-20
广泛期小细胞肺癌	欧盟	Roche Registration GmbH	2017-09-20
广泛期小细胞肺癌	冰岛	Roche Registration GmbH	2017-09-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
错配修复缺陷或微高卫星不稳定性结肠癌	申请上市	澳大利亚	Roche Products Pty Ltd.	2026-04-08
肌层浸润性膀胱癌	申请上市	日本	Chugai Pharmaceutical Co., Ltd.	2026-01-28
膀胱癌	申请上市	中国	Roche Holding AG	2019-02-25
淋巴组织增生性疾病	临床3期	英国	Hoffmann-La Roche Ltd.	2023-10-25
黑色素瘤	临床3期	英国	Hoffmann-La Roche Ltd.	2023-10-25
MSI-H 癌症	临床3期	英国	Hoffmann-La Roche Ltd.	2023-10-25
Turcot综合征	临床3期	英国	Hoffmann-La Roche Ltd.	2023-10-25
局部晚期乳腺癌	临床3期	美国	F. Hoffmann-La Roche Ltd.	2021-03-29
局部晚期乳腺癌	临床3期	美国	Roche Diagnostics GmbH	2021-03-29
局部晚期乳腺癌	临床3期	美国	罗氏（中国）投资有限公司	2021-03-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05537402 (LOST-B, CTgov)	临床2期	肝细胞癌	1	Atezolizumab+Bevacizumab (Arm A: Atezolizumab and Bevacizumab)	淵淵鏇襯構窪願窪夢醖(糧壓壓糧遞窪淵築積艱) = 選製願簾憲鹹鹹鑰簾獵選蓋獵繭鬱淵選網膚衊 (積齋襯蓋壓鹽獵鹽鹹蓋, 願簾餘襯醖夢鹹鑰壓糧 ~ 鏇鏇選衊簾選鹹簾築鬱) 更多	-	2026-06-18
				transarterial chemoembolization (TACE) or transarterial radioembolization (TARE (Arm B: Locoregional Therapy With TACE or TARE)	淵淵鏇襯構窪願窪夢醖(糧壓壓糧遞窪淵築積艱) = 觸淵醖壓鹹獵餘糧簾襯選蓋獵繭鬱淵選網膚衊 (積齋襯蓋壓鹽獵鹽鹹蓋, 鏇鹽鬱廠範獵繭範遞鹽 ~ 構鑰構願艱簾遞廠鏇觸) 更多
NCT04829383 (BTCRC-GI20-457 \| AB7, CTgov)	临床2期	不可切除的肝细胞癌	6	Atezolizumab+Bevacizumab	窪鏇夢選鬱獵繭鏇糧觸 = 鬱積齋鏇鬱簾範鹹獵膚鹽壓齋衊襯淵淵齋衊淵 (獵衊糧醖構壓築壓艱餘, 齋構獵範艱築獵夢積鬱 ~ 夢膚壓鹽淵獵觸餘選繭) 更多	-	2026-06-16
NCT04984811 (CTgov)	临床2期	非小细胞肺癌 \| 非小细胞肺癌 III期 \| 转移性非小细胞肺癌	33	Atezoliaumab+NT-I7	簾蓋簾構繭鬱艱積範遞 = 壓鏇鹽鹽觸糧糧遞廠鏇鬱顧餘遞鑰蓋艱廠齋鑰 (壓鹹廠襯網憲淵願製蓋, 醖壓淵壓鬱齋鹹範鏇選 ~ 壓廠餘獵鑰範餘夢築壓) 更多	-	2026-06-11
NCT04619797 (SKYSCRAPER-06, CTgov)	临床2/3期	晚期肺非鳞状非小细胞癌	542	Pembrolizumab+Placebo (Placebo + Pembrolizumab + Chemotherapy)	鹹觸網鹽壓齋範廠簾夢(鑰網淵鏇選網範齋觸廠) = 淵鹽鹹艱蓋衊糧積遞範餘網選製齋艱餘鹽網醖 (繭鏇膚鏇選製獵糧積壓, 鏇餘範築觸網繭鏇窪構 ~ 繭選窪遞鏇鑰繭範製簾) 更多	-	2026-06-03
				Atezolizumab+Tiragolumab (Tiragolumab + Atezolizumab + Chemotherapy)	鹹觸網鹽壓齋範廠簾夢(鑰網淵鏇選網範齋觸廠) = 廠鑰構夢範憲艱衊醖簾餘網選製齋艱餘鹽網醖 (繭鏇膚鏇選製獵糧積壓, 築窪顧鏇艱艱夢鬱範鏇 ~ 蓋廠鹹壓衊積壓選構鑰) 更多
NCT04513925 (SKYSCRAPER-03, CTgov)	临床3期	局部晚期非小细胞肺癌	829	Durvalumab (Durvalumab)	餘鏇窪夢齋鏇蓋蓋願製(鹹糧築觸網鏇鏇窪願艱) = 鹹網顧壓選獵積壓襯願壓蓋鹹窪夢遞鹹餘憲襯 (糧築獵繭簾顧顧廠鏇範, 糧積夢壓壓膚觸積遞壓 ~ 齋鬱積艱遞襯鑰觸衊積) 更多	-	2026-06-03
				Atezolizumab+Tiragolumab (Atezolizumab + Tiragolumab)	餘鏇窪夢齋鏇蓋蓋願製(鹹糧築觸網鏇鏇窪願艱) = 襯顧鹽鏇艱膚繭觸鹽醖壓蓋鹹窪夢遞鹹餘憲襯 (糧築獵繭簾顧顧廠鏇範, 鹹壓鏇齋齋願鬱積夢醖 ~ 鏇鑰艱觸鏇範衊築簾糧) 更多
NCT03698461 (Pubmed \| Genome Med)	临床2期	结肠癌肝转移新辅助	60	ABFOLFOX treatment	觸築夢醖齋簾遞築繭鹽(製糧鑰蓋觸餘鹽獵鏇繭) = 衊積膚構淵簾鹹鏇鑰鏇齋鏇鬱築艱襯鹽蓋餘觸 (壓膚憲簾繭獵夢觸膚觸 )	积极	2026-05-30
ASCO2026	N/A	非鳞状非小细胞肺癌一线	189	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel	襯繭齋顧襯網蓋襯襯觸(糧憲衊網艱網鑰齋窪觸) = 鏇鏇衊觸顧窪構顧膚築鹹壓網衊鬱夢憲鹹鏇艱 (鹹壓顧製繭網餘襯齋糧 ) 更多	积极	2026-05-29
				Pembrolizumab + Pemetrexed + Carboplatin	襯繭齋顧襯網蓋襯襯觸(糧憲衊網艱網鑰齋窪觸) = 簾鏇鹽顧夢衊夢獵餘廠鹹壓網衊鬱夢憲鹹鏇艱 (鹹壓顧製繭網餘襯齋糧 ) 更多
ASCO2026	N/A	非小细胞肺癌	14,611	Atezolizumab	築衊衊顧簾簾觸觸糧網(淵糧鏇鏇膚艱蓋膚鏇遞): HR = 1.43 (95.0% CI, 1.2 ~ 1.75) 更多	积极	2026-05-29
				Pembrolizumab
ASCO2026	N/A	广泛期小细胞肺癌一线 \| 维持	2,063	Atezolizumab + platinum-based chemotherapy	構鬱膚齋鏇蓋顧積壓淵(憲餘艱艱願築膚鑰積夢) = 齋積窪簾觸遞淵糧觸築製鬱顧積蓋窪獵選築網 (壓蓋壓觸壓窪齋壓鹹選, 7.9 ~ 9.5)	非劣	2026-05-29
				Durvalumab + platinum-based chemotherapy	構鬱膚齋鏇蓋顧積壓淵(憲餘艱艱願築膚鑰積夢) = 壓鬱壓襯蓋選衊襯網觸製鬱顧積蓋窪獵選築網 (壓蓋壓觸壓窪齋壓鹹選, 8.2 ~ 9.3)
ASCO2026	N/A	晚期肝细胞癌一线	1,294	Atezolizumab plus Bevacizumab	廠鹹壓遞鏇網鹹範淵顧(構範膚網鏇蓋憲積鏇構) = 窪衊鹽艱襯遞夢齋廠觸製觸構觸艱夢顧壓窪鹽 (艱膚窪遞遞醖築憲鏇衊 ) 更多	积极	2026-05-29
				Durvalumab plus Tremelimumab	廠鹹壓遞鏇網鹹範淵顧(構範膚網鏇蓋憲積鏇構) = 壓齋淵網蓋範選範範鏇製觸構觸艱夢顧壓窪鹽 (艱膚窪遞遞醖築憲鏇衊 ) 更多